0HTC trade ideas
Energy building in this biotech stockVery nice symmetry in this H&S pattern. I expect an explosive move
CARAInverted head and shoulder LONG position idea with Fibonacci extension target head as SL
NASDAQ:CARA
CARA Big Rectangular BottomAn analysis for Cara
a rectangle has formed
currently sitting at middle point of rectangle. I would short this.
Interesting price action
I might do some more development on CARA
CARA Therapeutics, Inc. targets $cara CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
CARA looks like it wants the CARA de MOONCara Therapeutics, Inc. (CARA) highly impulsive ... i do not like stocks in a toppy market, but this being a biotech and technically speaking, i would place a stoploss or trailing stop as it approaches highs between 25 and 27, watchful for breakout to upside or downside... she looks like she wants 30+ before retracing potentially as deep as it has done in the past.
Cara, the Cannabis Pharma Sector leaderLight weight company with a strong cannabis product niche. Technical bullflag setup, needs macro bull trend to hold up, and then a company specific catalyst to breakout for new ATHs
CARA in equilibriumInitial spike in volume was caused by fast track and phase 3 news. Nothing to drive the price at the moment. My best best is that we'll see CARA retest $19.65 within a week or so.
CARA Will Be a Huge Winner!!! $100 in 1 6-12 monthsNASDAQ:CARA Has been consolidating for over 5 years now and is flirting with its ATH.
The promising biotech company only has a market cap of $1B which makes a 5x move very easy and fast. This is more of a longer-term play and can increase well over 5x
Stock may dip before the meteoric rise but hard to say with earnings coming first week of August.
Thank you for reading.
Best,
Antonio
Cara Therapeutics - Outbreak or Selloff?Cara Therapeutics is back on the strong resistance line that has been tested 4 times. Only once, in June 2017, was this briefly broken after FDA breakthrough therapy designation.
CR845 reduces itching in patients with chronic liver insufficiency. This brought in June 2018 3 large pharmaceutical companies on the plan, who wanted to market this product against once and milestone payments.
Outlook:
To confirm the breakout, a week-end above the blue resistance line is necessary. Following this, a retest of this resistance would be ideal to confirm this as a support zone.
If share price can not establish a weekly close above, is to expect a subsequent sale.
greeting
Stefan Bode
CARA to meet 50MA soon?I think we may have topped out for now. If you are not in a bullish position right now, perhaps it is wise to hold until resistance is broken, or wait for it to retrace to the 50MA. Indicators show that we're a tiny tad extended atm.
Take a look at ZYNE, if CBD Pharma is your game.
Just my 2 cents. It's free. Trade with caution.
Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™finance.yahoo.com
finance.yahoo.com
So what
Any time a clinical-stage biotech announces positive results for its lead candidate, it's good news. But today's results are especially great for Cara for several reasons.
The improvement in itching for patients receiving Korsuva was off the charts. The key metric in determining statistical significance in clinical studies is the p-value, a calculated probability of how meaningful the obtained results actually are. A p-value of 0.05 or less is considered to be statistically significant. For the primary endpoint in Cara's study, the p-value was 0.000019.
Cara Therapeutics CEO Derek Chalmers noted that the company was "particularly encouraged by the early response with Korsuva injection." He said that the statistically significant difference between Korsuva and placebo was observed after only one week of treatment. Even better, the significant benefit from Korsuva was sustained through 12 weeks.
Also, Korsuva didn't raise any safety concerns. There were some adverse events for patients in the phase 3 study, but they were similar across patients taking Korsuva and those on placebo. The most common adverse event was diarrhea, which was reported for 9.5% of the patients receiving Korsuva injection versus 3.7% of the patients in the placebo group.
Now what
This was a critical step for Cara, but there are still a couple of hurdles to jump. The biotech must complete another ongoing phase 3 clinical study of Korsuva injection in treating CKD-aP patients on hemodialysis. Cara expects to announce the results from this second study later this year. If those results are positive, the company will move quickly to file for U.S. regulatory approval of the drug.
There's no sure thing when it comes to the regulatory approval process. But based on what Cara announced today, the chances of eventual approval of Korsuva in the CKD-aP indication appear to be quite good.
$CARA HIGHLY UNUSUAL OPTIONS ACTIVITY. CANNABIS V OPIOIDCara Therapeutics was flagged on friday due to the exceptionally high amount of options traded, over 340% above the average volume. NASDAQ:CARA disappointed investors with first quarter results with a higher loss than expected, but the company has $156 million in cash available to continue to develop new Cannabinoid drugs. Cara specialises in the development of pain relief drugs and their current project is seen as a means of replacing the highly addictive Opioids.
The stock is currently sitting on support while selling of in sympathy with the entire market, a bounce would present a good entry. To complete the EW count, $25 is a maximum wave 5 target in our opinion, while setting $22.50 as your initial target to bank profits.
ANALYSTS PRICE TARGET $26.02
ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 17%
COMPANY PROFILE
CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain.
CARA Put SaleI have a Aug put sale because the IV is 150%, the strike price is at resistance and the stock is on an uptrend.
If the price gaps in this red box (Or below $17.20), I will begin to be nervous.
CARA- Broke the triangle channel to get a support at 14.10$.
- Forming a hammer may be followed by a confirmation the next day
- The target is about 18i$h
$CARA is Giving a Buy Signal$CARA Therapeutics looks to be a good buy choice for the Tuesday market open. For information on how to access the Megalodon indicator, just send me a message!
